S&CO Inc. Has $2.52 Million Stock Holdings in Elanco Animal Health Incorporated $ELAN

S&CO Inc. trimmed its stake in Elanco Animal Health Incorporated (NYSE:ELAN) by 21.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 111,284 shares of the company’s stock after selling 30,000 shares during the quarter. S&CO Inc.’s holdings in Elanco Animal Health were worth $2,518,000 as of its most recent SEC filing.

Other large investors have also bought and sold shares of the company. Huntington National Bank grew its holdings in Elanco Animal Health by 136.7% in the third quarter. Huntington National Bank now owns 1,882 shares of the company’s stock worth $38,000 after purchasing an additional 1,087 shares during the period. Whittier Trust Co. of Nevada Inc. grew its stake in Elanco Animal Health by 80.3% in the third quarter. Whittier Trust Co. of Nevada Inc. now owns 2,021 shares of the company’s stock valued at $42,000 after acquiring an additional 900 shares during the period. Torren Management LLC acquired a new stake in Elanco Animal Health in the fourth quarter valued at approximately $46,000. Fifth Third Bancorp grew its stake in Elanco Animal Health by 3,018.3% in the third quarter. Fifth Third Bancorp now owns 2,900 shares of the company’s stock valued at $58,000 after acquiring an additional 2,807 shares during the period. Finally, Farther Finance Advisors LLC grew its stake in Elanco Animal Health by 43.6% in the fourth quarter. Farther Finance Advisors LLC now owns 3,089 shares of the company’s stock valued at $70,000 after acquiring an additional 938 shares during the period. 97.48% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on the company. Citigroup raised their price objective on Elanco Animal Health from $30.00 to $31.00 and gave the company a “buy” rating in a research note on Thursday, May 7th. UBS Group reissued a “buy” rating on shares of Elanco Animal Health in a research note on Tuesday, March 10th. Weiss Ratings cut Elanco Animal Health from a “sell (d+)” rating to a “sell (d)” rating in a research note on Monday. Wall Street Zen upgraded shares of Elanco Animal Health from a “buy” rating to a “strong-buy” rating in a report on Saturday. Finally, JPMorgan Chase & Co. lifted their price objective on shares of Elanco Animal Health from $28.00 to $30.00 and gave the company an “overweight” rating in a report on Thursday, May 7th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $28.20.

Elanco Animal Health Stock Down 8.3%

Shares of NYSE:ELAN opened at $19.85 on Friday. The business’s 50 day moving average is $23.31 and its 200 day moving average is $23.33. Elanco Animal Health Incorporated has a 12-month low of $12.40 and a 12-month high of $27.72. The stock has a market cap of $9.92 billion, a price-to-earnings ratio of -39.71, a PEG ratio of 2.31 and a beta of 1.69. The company has a quick ratio of 1.12, a current ratio of 2.16 and a debt-to-equity ratio of 0.60.

Elanco Animal Health (NYSE:ELAN) last announced its quarterly earnings results on Wednesday, May 6th. The company reported $0.40 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.34 by $0.06. Elanco Animal Health had a positive return on equity of 7.42% and a negative net margin of 4.95%.The business had revenue of $1.37 billion during the quarter, compared to the consensus estimate of $1.28 billion. During the same quarter in the prior year, the company posted $0.37 earnings per share. Elanco Animal Health’s revenue was up 14.9% compared to the same quarter last year. Elanco Animal Health has set its Q2 2026 guidance at 0.250-0.285 EPS and its FY 2026 guidance at 1.030-1.090 EPS. On average, sell-side analysts forecast that Elanco Animal Health Incorporated will post 1.11 earnings per share for the current fiscal year.

About Elanco Animal Health

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.